Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Study of BHV-8000 in Early Parkinson’s Disease
2025-521113-13-00Phase 3Authorised
- Sponsor
- Biohaven Ltd.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing BHV-8000 with Placebo (2 arms). Primary endpoint: Time to first qualifying worsening event on MDS-UPDRS Part II. Planned start Dec 2025; status: authorised.
02
Drugs
BHV-8000
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-521113-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521113-13-00.